Title
Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature
Date Issued
01 January 2022
Access level
open access
Resource Type
journal article
Author(s)
Pasin C.
Ganetsky A.
Harle D.
Wang X.K.
Belay K.
Richman L.P.
Huffman A.P.
Vonderheide R.H.
Yates A.J.
Porter D.L.
Wang Y.
Zhang Y.
Reshef R.
Columbia University Irving Medical Center
Publisher(s)
Elsevier B.V.
Abstract
Vitamin D promotes a shift from a proinflammatory to a more tolerogenic immune state in allogeneic hematopoietic cell transplant (HCT) recipients. The dominant mechanism responsible for this shift has not been elucidated. We took a multifaceted approach to evaluating the clinical and immunologic impact of low vitamin D levels in 53 HCT recipients. We used 28-plex flow cytometry for immunophenotyping, serum cytokine levels, T-cell cytokine production, and T-cell whole genome transcription. The median day-30 vitamin D level was 20 ng/mL, and deficiency was common in younger patients undergoing myeloablative transplantation. Low vitamin D levels were associated with a high CD8/Treg ratio, increased serum levels and T-cell production of proinflammatory cytokines, and a gene expression signature of unrestrained T-cell proliferation and epigenetic modulation through the PRC2/EZH2 complex. Immunophenotyping confirmed a strong association between high levels of vitamin D and an activated EZH2 signature, characterized by overexpression of ID3, which has a role in effector T-cell differentiation. Our findings demonstrate the critical role of vitamin D in modulating T-cell function in human GVHD and identify a previously undescribed interaction with EZH2 and ID3, which may impact effector differentiation and has implications to cell therapies and other forms of cancer immunotherapy. © 20XX American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Start page
18.e1
End page
18.e10
Volume
28
Issue
1
Language
English
OCDE Knowledge area
Patología Inmunología Biología celular, Microbiología Oncología
Scopus EID
2-s2.0-85119128895
PubMed ID
Source
Transplantation and Cellular Therapy
ISSN of the container
26666367
Sponsor(s)
Financial disclosure: National Institutes of Health grants HL143424 to R.R. HL127351 to Y.Z. CA16520 to D.L.P. and R.H.V. AI093870 to A.J.Y. and CA013696 to the flow cytometry core at the Herbert Irving Comprehensive Cancer Center, Columbia University, Conflict of interest statement: R.H.V. reports consulting fees or honoraria from Medimmune and Verastem and research funding from Fibrogen, Janssen, and Lilly; he is a member of the Lustgarten Therapeutics Advisory working group, is an inventor on licensed patents relating to cancer cellular immunotherapy and cancer vaccines, and receives royalties from Children's Hospital Boston for a licensed research-only monoclonal antibody. D.L.P. reports consulting fees or honoraria from Novartis, Kite/Gilead, Incyte, Glenmark, Janssen and Adepcet Bio; he is an inventor on licensed patents to Tmunity and Novartis, owns stock in Roche/Genentech, and is a Board Member at the National Marrow Donor Program. R.R. reports consulting fees or honoraria from Gilead, Novartis, BMS, Bayer, Synthekine, Atara, TScan and Regeneron. Financial disclosure: See Acknowledgments on page 18.e9.
Sources of information: Directorio de Producción Científica Scopus